Lineage Cell Therapeutics Inc (LCTX)
1.14
-0.01
(-0.87%)
USD |
NYAM |
Apr 22, 16:00
1.16
+0.02
(+1.75%)
Pre-Market: 08:30
Lineage Cell Therapeutics Profit Margin (Quarterly): -228.7% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -228.7% |
| September 30, 2023 | -570.6% |
| June 30, 2023 | -162.1% |
| March 31, 2023 | -183.2% |
| December 31, 2022 | -331.8% |
| September 30, 2022 | -202.4% |
| June 30, 2022 | -148.5% |
| March 31, 2022 | -135.3% |
| December 31, 2021 | -3.02K% |
| September 30, 2021 | -355.3% |
| June 30, 2021 | -1.09K% |
| March 31, 2021 | -483.3% |
| December 31, 2020 | |
| September 30, 2020 | -2.27K% |
| June 30, 2020 | -6.59K% |
| March 31, 2020 | -5.06K% |
| December 31, 2019 | -538.7% |
| September 30, 2019 | -7.61K% |
| June 30, 2019 | -12.01K% |
| March 31, 2019 | |
| December 31, 2018 | -26.29K% |
| September 30, 2018 | |
| June 30, 2018 | -695.5% |
| March 31, 2018 | -16.95K% |
| December 31, 2017 | -12.64K% |
| Date | Value |
|---|---|
| September 30, 2017 | |
| June 30, 2017 | -3.06K% |
| March 31, 2017 | |
| December 31, 2016 | -669.5% |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | -2.92K% |
| December 31, 2015 | -2.42K% |
| September 30, 2015 | -1.62K% |
| June 30, 2015 | -1.69K% |
| March 31, 2015 | -1.80K% |
| December 31, 2014 | -2.38K% |
| September 30, 2014 | -1.52K% |
| June 30, 2014 | -2.04K% |
| March 31, 2014 | -1.65K% |
| December 31, 2013 | -1.56K% |
| September 30, 2013 | -1.63K% |
| June 30, 2013 | -1.44K% |
| March 31, 2013 | -1.47K% |
| December 31, 2012 | -1.16K% |
| September 30, 2012 | -882.3% |
| June 30, 2012 | -1.51K% |
| March 31, 2012 | -1.98K% |
| December 31, 2011 | |
| September 30, 2011 | -321.8% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-12.01K%
Minimum
Jun 2019
-135.3%
Maximum
Mar 2022
-2.28K%
Average
-511.0%
Median
Profit Margin (Quarterly) Benchmarks
| Acumen Pharmaceuticals Inc | -- |
| Sarepta Therapeutics Inc | 11.51% |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | -19.35K% |
| IGC Pharma Inc | -2.74K% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -31.51% |
| Return on Assets | -19.33% |
| Return on Invested Capital | -31.51% |
| Gross Profit Margin (Quarterly) | 87.74% |
| Operating Margin (Quarterly) | -304.7% |
| Return on Net Operating Assets | -34.13% |